Palatin Technologies, Inc. (PTN)
Market Cap | 30.34M |
Revenue (ttm) | 5.90M |
Net Income (ttm) | -32.88M |
Shares Out | 16.14M |
EPS (ttm) | -2.51 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 70,895 |
Open | 1.890 |
Previous Close | 1.860 |
Day's Range | 1.800 - 1.900 |
52-Week Range | 1.430 - 5.650 |
Beta | 0.94 |
Analysts | Strong Buy |
Price Target | 17.00 (+804.26%) |
Earnings Date | May 15, 2024 |
About PTN
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide m... [Read more]
Financial Performance
In 2023, PTN's revenue was $4.85 million, an increase of 230.53% compared to the previous year's $1.47 million. Losses were -$27.54 million, -23.91% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PTN stock is "Strong Buy" and the 12-month stock price forecast is $17.0.
News
![](https://cdn.snapi.dev/images/v1/y/p/press4-2489887.jpg)
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mo...
![](https://cdn.snapi.dev/images/v1/u/k/press19-2487679.jpg)
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5i treatment Data from this Phase 2 clinical study is expected by end of calendar year 2024 Publishe...
![](https://cdn.snapi.dev/images/v1/2/y/press8-2475259.jpg)
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end of calendar year 2024 Additiona...
![](https://cdn.snapi.dev/images/v1/q/d/press8-2431749.jpg)
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P
![](https://cdn.snapi.dev/images/v1/n/z/conf5-2420557.jpg)
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
CRANBURY, N.J. , May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before the o...
![](https://cdn.snapi.dev/images/v1/e/w/press14-2405733.jpg)
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar year-end 2024 Hosting virtual KOL event "Beyond GLPs" on May 8, 2024 Focus will be on Company's met...
![](https://cdn.snapi.dev/images/v1/w/v/press2-2399376.jpg)
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
CRANBURY, N.J. , April 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ac...
![](https://cdn.snapi.dev/images/v1/q/j/press17-2360710.jpg)
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Positive Phase 3 Study Results Included in Dr. Eric Donnenfeld's Presentation Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P
![](https://cdn.snapi.dev/images/v1/o/0/press15-2298181.jpg)
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met , Statistical Significance (P
![](https://cdn.snapi.dev/images/v1/s/j/press13-2277805.jpg)
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED) – Topline Data Expected in February Oral ...
![](https://cdn.snapi.dev/images/v1/j/b/conf14-2269114.jpg)
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
CRANBURY, N.J. , Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before...
![](https://cdn.snapi.dev/images/v1/f/f/press9-2259575.jpg)
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Top-Line Results Expected in February CRANBURY, N.J. , Feb. 5, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines bas...
![](https://cdn.snapi.dev/images/v1/u/u/press4-2256533.jpg)
Palatin Announces Closing of $10 Million Registered Direct Offering
CRANBURY, N.J. , Feb. 1, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mol...
![](https://cdn.snapi.dev/images/v1/d/g/press4-2250570.jpg)
Palatin Announces $10 Million Registered Direct Offering
CRANBURY, N.J. , Jan. 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mo...
![](https://cdn.snapi.dev/images/v1/s/w/press6-2220572.jpg)
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 Study Data Base Lock 2H January 2024 Topline Data Readout Expected Early 1Q Calendar Year 2024 Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Stud...
![](https://cdn.snapi.dev/images/v1/e/y/press19-2214575.jpg)
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #HSDD--Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
![](https://cdn.snapi.dev/images/v1/i/9/press2-2203291.jpg)
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin's focus is solely on its development and clinical pipeline based on the melanocortin receptor system C...
![](https://cdn.snapi.dev/images/v1/z/4/press15-2200915.jpg)
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
CRANBURY, N.J. , Dec. 18, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the act...
![](https://cdn.snapi.dev/images/v1/o/f/press9-2156589.jpg)
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) 570 Patients Enrolled Topline Data Currently Expected Late 4Q Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in ...
![](https://cdn.snapi.dev/images/v1/b/k/conf11-2149472.jpg)
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
CRANBURY, N.J. , Nov. 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before t...
![](https://cdn.snapi.dev/images/v1/k/u/press4-2118592.jpg)
Palatin Announces Closing of $5 Million Registered Direct Offering
CRANBURY, N.J. , Oct. 24, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mo...
![](https://cdn.snapi.dev/images/v1/r/z/press11-2114951.jpg)
Palatin Announces $5 Million Registered Direct Offering
CRANBURY, N.J. , Oct. 23, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mo...
![](https://cdn.snapi.dev/images/v1/o/j/press16-2110760.jpg)
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed $4.6 million in Gross Product Revenue 11% growth over prior quarter; 100% growth over comparable quarter la...
![](https://cdn.snapi.dev/images/v1/u/b/press18-2108441.jpg)
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
Positive data with Palatin's melanocortin-4 receptor (MC4R) agonist plus glucagon like peptide-1 (GLP-1) presented at the Peptide Therapeutics Symposium GLP-1 & MC4R agonist co-administration data sho...
![](https://cdn.snapi.dev/images/v1/y/8/press8-2104296.jpg)
Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
Data demonstrates oral PL8177 causes diseased colons to move to a healthier state Provides further support for ongoing oral PL8177 Phase 2 ulcerative colitis study CRANBURY, N.J. , Oct. 16, 2023 /PRNe...